Trial Profile
Continuous infusion of campath-1H followed by subcutaneous injections in previously treated patients with chronic lymphocytic leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2012
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 30 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 20 Oct 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 09 Jan 2007 Status change